BACKGROUND Ascites is a common clinical sign noted in 3% to 4% of hospitalized medical patients. Nearly 94% of patients with ascites have non-malignant etiologies, with the most common being chronic ...

Ghent, Belgium – 14 April 2025 – Sequana Medical NV (Euronext Brussels: SEQUA, the "Company" or "Sequana Medical"), a pioneer in the treatment of drug-resistant fluid overload in liver disease ...

Background: Ascites and pleural effusion are well recognized complications of pancreatic diseases. Drug therapy of these is limited by high cost, prolonged hospitalization and failure rates ...

The main symptoms and complications of portal hypertension include ascites (fluid buildup in the abdomen), dilated veins or varices, and bleeding from varices. Doctors make the diagnosis of portal ...

3) In advanced cases, this abdominal fluid accumulation (called ascites) may become visibly noticeable as increasing waistline expansion that doesn’t correspond to weight gain elsewhere in the body.

Rein advanced the clinical development of its lead asset, LTI-03, and aims to initiate a Phase 2 trial for the treatment of idiopathic pulmonary fibrosis (IPF) in the first half of 2025 Positive ...

Your liver plays a crucial role in keeping your body healthy, and taking care of it should be a priority. Liver disease is silently creeping into more and more lives in India, and cirrhosis is one ...

Rein's second product candidate, LTI-01, is a proenzyme that has completed Phase 1b and Phase 2a clinical trials for the treatment of loculated pleural effusions. LTI-01 has received Orphan Drug ...

The Company received US FDA approval for the alfapump System for the treatment of recurrent or refractory ascites due to liver cirrhosis in December 2024, following the grant of FDA Breakthrough ...

Seventeen (60.7%) had evidence of underlying chronic pancreatitis on imaging studies, 10 (35.7%) had a preceding episode of acute pancreatitis and 1 (3.6%) developed ascites following respective ...